Yu-Hsiang Hsieh1, Andrea F Dugas1, Frank LoVecchio2, Breana McBryde1, Erin P Ricketts1, Kathryn Saliba-Shaw1, Richard E Rothman1,3. 1. Department of Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 2. Department of Emergency Medicine, University of Arizona College of Medicine, Phoenix, Arizona, USA. 3. Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Abstract
BACKGROUND: Peramivir offers a single-dose intravenous (IV) treatment option for influenza (vs 5-day oral dosing for oseltamivir). We sought to compare outcomes of emergency department (ED) patients at high risk for influenza complications treated withIV peramivir vs oral oseltamivir. METHODS:During the 2015-16 and 2016-17 influenza seasons, adult patients in two US EDs were randomized to either oral oseltamivir or IV peramivir treatment group. Eligibility included positive molecular influenza test; met CDC criteria for antiviral treatment; able to provide informed consent and agree to follow-up assessment. Outcomes were measured by clinical end-point indicators, including FLU-PRO Score, Ordinal Scale, Patient Global Impression on Severity Score, and Karnofsky Performance Scale for 14 days. Non-inferior t test was performed to assess comparative outcomes between the two groups. RESULTS:Five hundred and seventy-five (68%) of 847 influenza-positive patients were approached. Two hundred and eighty-four met enrollment criteria and 179 were enrolled; of these 95 (53%) were randomized to peramivir, and 84 tooseltamivir. Average FLU-PRO score at baseline was similar (peramivir: 2.67 vs oseltamivir: 2.52); the score decreased over time for both groups (day 5: peramivir: 1.71 vs oseltamivir: 1.62; day 10: peramivir: 1.48 vs oseltamivir: 1.37; day 14: peramivir: 1.40 vs oseltamivir: 1.33; all P < .05 for significantly non-inferior). Influenza-related complications were similar between two groups (All: peramivir: 31% vs oseltamivir: 21%, P > .05; pneumonia: peramivir: 11% vs oseltamivir: 14%, P > .05). CONCLUSIONS: Clinical outcomes of influenza-infected patients treated with single-dose IV peramivir were comparable to those treated with oral oseltamivir, suggesting potential utility of peramivir for influenza-infected patients in the ED.
RCT Entities:
BACKGROUND:Peramivir offers a single-dose intravenous (IV) treatment option for influenza (vs 5-day oral dosing for oseltamivir). We sought to compare outcomes of emergency department (ED) patients at high risk for influenza complications treated with IV peramivir vs oral oseltamivir. METHODS: During the 2015-16 and 2016-17 influenza seasons, adult patients in two US EDs were randomized to either oral oseltamivir or IV peramivir treatment group. Eligibility included positive molecular influenza test; met CDC criteria for antiviral treatment; able to provide informed consent and agree to follow-up assessment. Outcomes were measured by clinical end-point indicators, including FLU-PRO Score, Ordinal Scale, Patient Global Impression on Severity Score, and Karnofsky Performance Scale for 14 days. Non-inferior t test was performed to assess comparative outcomes between the two groups. RESULTS: Five hundred and seventy-five (68%) of 847 influenza-positive patients were approached. Two hundred and eighty-four met enrollment criteria and 179 were enrolled; of these 95 (53%) were randomized to peramivir, and 84 to oseltamivir. Average FLU-PRO score at baseline was similar (peramivir: 2.67 vs oseltamivir: 2.52); the score decreased over time for both groups (day 5: peramivir: 1.71 vs oseltamivir: 1.62; day 10: peramivir: 1.48 vs oseltamivir: 1.37; day 14: peramivir: 1.40 vs oseltamivir: 1.33; all P < .05 for significantly non-inferior). Influenza-related complications were similar between two groups (All: peramivir: 31% vs oseltamivir: 21%, P > .05; pneumonia: peramivir: 11% vs oseltamivir: 14%, P > .05). CONCLUSIONS: Clinical outcomes of influenza-infectedpatients treated with single-dose IV peramivir were comparable to those treated with oral oseltamivir, suggesting potential utility of peramivir for influenza-infectedpatients in the ED.
Authors: Fiona Havers; Brendan Flannery; Jessie R Clippard; Manjusha Gaglani; Richard K Zimmerman; Lisa A Jackson; Joshua G Petrie; Huong Q McLean; Mary Patricia Nowalk; Michael L Jackson; Arnold S Monto; Edward A Belongia; Heather F Eng; Lois Lamerato; Angela P Campbell; Alicia M Fry Journal: Clin Infect Dis Date: 2015-02-25 Impact factor: 9.079
Authors: Richard Whitley; Alan Laughlin; Simon Carson; Essack Mitha; Guy Tellier; Mark Stich; Jenna Elder; W James Alexander; Sylvia Dobo; Phil Collis; William P Sheridan Journal: Antivir Ther Date: 2014-10-15
Authors: Andrea F Dugas; Yu-Hsiang Hsieh; Frank LoVecchio; Gregory J Moran; Mark T Steele; David A Talan; Richard E Rothman Journal: Clin Infect Dis Date: 2020-01-01 Impact factor: 9.079
Authors: John H Powers; Elizabeth D Bacci; Nancy K Leidy; Jiat-Ling Poon; Sonja Stringer; Matthew J Memoli; Alison Han; Mary P Fairchok; Christian Coles; Jackie Owens; Wei-Ju Chen; John C Arnold; Patrick J Danaher; Tahaniyat Lalani; Timothy H Burgess; Eugene V Millar; Michelande Ridore; Andrés Hernández; Patricia Rodríguez-Zulueta; Hilda Ortega-Gallegos; Arturo Galindo-Fraga; Guillermo M Ruiz-Palacios; Sarah Pett; William Fischer; Daniel Gillor; Laura Moreno Macias; Anna DuVal; Richard Rothman; Andrea Dugas; M Lourdes Guerrero Journal: PLoS One Date: 2018-03-22 Impact factor: 3.240
Authors: Suma Vupputuri; Kevin B Rubenstein; Alphonse J Derus; Bernadette C Loftus; Michael A Horberg Journal: PLoS One Date: 2019-04-03 Impact factor: 3.240
Authors: Yu-Hsiang Hsieh; Andrea F Dugas; Frank LoVecchio; Breana McBryde; Erin P Ricketts; Kathryn Saliba-Shaw; Richard E Rothman Journal: Influenza Other Respir Viruses Date: 2020-10-02 Impact factor: 4.380
Authors: Sphamandla E Mtambo; Samuel C Ugbaja; Aganze G Mushebenge; Bahijjahtu H Abubakar; Mthobisi L Ntuli; Hezekiel M Kumalo Journal: Molecules Date: 2022-03-02 Impact factor: 4.411
Authors: Yu-Hsiang Hsieh; Andrea F Dugas; Frank LoVecchio; Breana McBryde; Erin P Ricketts; Kathryn Saliba-Shaw; Richard E Rothman Journal: Influenza Other Respir Viruses Date: 2020-10-02 Impact factor: 4.380